On August 24, 2026 BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, reported that it is entering the clinic next quarter. BreakBio aims to be not first-in-class but best-in-class. It is designed for both higher efficacy than Moderna or BioNTech and it is also designed to treat more cancer indications than Moderna or BioNTech.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BreakBio is designed for higher efficacy than Moderna’s individualized neoantigen therapy (INT). Higher efficacy because BreakBio is designed to find better targets per patient. It is an AI first biotech company. For every patient, its platform integrates highest quality tumor DNA sequencing, RNA sequencing, mass-spectrometry-based immunopeptidomics (of that patient) with proprietary deep AI analysis to find better targets on that patient’s cancer cells. Better targets means killing more (or all) of the cancer cells.

BreakBio is designed to extend personalized drugs to more cancer indications than Moderna. BreakBio achieves this by targeting not just neoantigens (associated with mutations as Moderna and BioNTech do) but it also searches for and finds, in each patient, some of the hundreds of cancer-associated non-mutated proteins such as cancer testis antigens, embryonic antigens, etc. – so BreakBio is designed to also work for low mutational cancers, which means it is designed to work for all solid cancers both high mutational cancers like melanoma and low mutational cancers like colorectal.

(Press release, BreakBio, AUG 24, 2026, View Source [SID1234670302])